Key terms
About APTO
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest APTO news
Yesterday
4:44pm ET
Aptose Biosciences Enhances Executive Compensation and Roles
Apr 03
7:06am ET
Piper Sandler Keeps Their Buy Rating on Aptose Biosciences (APTO)
Mar 28
7:10am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 27
5:05pm ET
Aptose Biosciences’ Strategic Shift to Front-Line AML Therapy Garners Buy Rating
Mar 26
4:38pm ET
Aptose Biosciences Expands AML Treatment Trials
Mar 26
4:15pm ET
Aptose Biosciences proceeds from closing of public offering Jan 30 $9.7M
Mar 26
4:12pm ET
Aptose Biosciences reports FY23 EPS ($7.58) vs ($6.80) last yeat
Mar 18
5:07pm ET
Aptose Biosciences Unveils Upcoming Financials
Mar 18
5:04pm ET
Aptose Biosciences Clarifies Regulatory Compliance Measures
Feb 01
9:00am ET
Aptose Biosciences price target lowered to $5 from $12 at Piper Sandler
Feb 01
8:09am ET
Piper Sandler Sticks to Its Buy Rating for Aptose Biosciences (APTO)
No recent press releases are available for APTO
APTO Financials
Key terms
Ad Feedback
APTO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
APTO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range